Abstract
Tumors of the central nervous system (CNS) are represented by a wide spectrum of histological subcategories,which include: astrocytoma, oligodendroglioma,ependymoma, mixed glioma, choroid plexus tumors, neuronal and mixed neuronal-glial tumors,pineal tumors, and germinomas (see Chap. 2). The estimated incidence rate for all primary tumors including benign and malignant lesions in 1999 was 11.8 per 100,000 population, with malignant tumors accounting for 6.5 per 100,000 (Landis et al. 1999).This resulted in approximately 16,800 new cases of brain and other nervous system tumors in the United States (9500 males and 7300 females). Glioblastoma multiforme, high-grade oligodendroglioma, and anaplastic astrocytoma are among the most difficult primary brain tumors to control, with an annual incidence in the United States of over 10,000 patients. Their natural history is relatively short with rapid tumor progression leading to the patient¡¯s death.Even though longer survival times have been obtained using better surgical techniques, contemporary radiotherapy, chemotherapy, or combinations thereof, no treatment is curative for a majority of these tumors
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bigner DD, Brown MT, Friedman AH, et al. (1998) Iodine-131-abeled antitenascin monoclonal antibody 81c6 treatment of patients with malignant gliomas: phase I trial results. J Clin Oncol 16(6):2202–2212
Boiardi A, Silvanni A, Ruffini PA, et al. (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphocyte activated killer cell (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39:193–197
Bourdon MA, Coleman RE, Blasberg RG, et al. (1984) Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res 4:133–140
Brady LW, et al. (1990) Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol 24:151–160; discussion 151–160
Brown MT, Coleman RE, Friedman AH, et al. (1996) Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 2(6):963–972
Bullard De, Adams CJ, Coleman RE, et al. (1986) In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.J Neurosurg 64:257–262
Embleton MJ, Rowland GF, Simmonds RG et al. (1983) Selective cytotoxicity against human tumor cells by a vindesinemonoclonal antibody conjugate. Br J Cancer 47:43–49
Emrich JG, Bender H, Class R et al. (1996) In vitro evaluation of iodine-125-labeled monoclonal antibody (Mab 425) in human high-grade glioma cells. Am J Clin Oncol 19(6):601–608
Hayes RL, Koslow M, Hiesiger EM, et al. (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated cell for adults with recurrent malignant gliomas. Cancer 76(5):840–852
Hopkins K, Chandler C, Bullimore J, et al. (1995) A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral ytrium-90 radioimmunoconjugates.Radiother Oncol 34(2):121–131
Jacobs SK, Wilson DJ, Kornblith PL, et al. (1986) In vitro killing of human glioblastoma by IL-2 activated autologous lymphocytes. J Neurosurg 64:114–117
Jansen FK, Blythman HE, Carriere D, et al. (1982) Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62: 185–216
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics 1999. CA Cancer J Clin 49:8–31
Merchant RE, Ellison MD, and Young HF (1990) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations. J Neurooncol 8:173+
Merchant RE, McVicar DW, Merchant LH, et al. (1992) Treatment of recurrent malignant gliomas by repeated intracerebral injection of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. A phase I clinical trial. J Neurooncol 12(1):75–83
Miller RA, Oseroff AR, Stratte PE, et al. (1983) Monoclonal antibody therapeutic trial in seven patients with T-cell lymphoma. Blood 62:988–995
Miyamoto CT, Brady LW, Rackover MA, et al. (1996) The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain.Recent Results Cancer Res 141:183–192
Nitta T, Sato K, Yagita H, et al. (1990) Preliminary trial of specific targetting therapy against malignant glioma. Lancet 335:368–376
Oldfield EH, Ram Z, Culver KW, et al. (1993) Gene therapy for the treatment of brain tumors using intra-tumoral transduction with thymidine kinase gene and intravenous gancyclovir. Hum Gene Ther 4:39–69
Ram Z, Culver KW, Walbridge S, et al. (1993) Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 79:400–407
Riva P, Franceschi G, Frattarelli M, et al. (1999) 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma - phase I and II study. Acta Oncol 38(3):351–359
Sankhla SK, Nadkarni JS, and Bhagwati SN (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin for recurrent malignant brain tumors.J Neurooncol 27(2):133–140
Snelling L, Miyamoto CT, Bender H, et al. (1995) Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of highgrade astrocytomas. Hybridoma 14(2):111–114
Stavrou D (1990) Monoclonal antibodies in neuro-oncology.Neurosurg Rev 13(1):7–18
Thorpe PE, Brown ANF, Bremmer JAG Jr, et al. (1985) An immunotoxin composed of monoclonal anti-Thy-1.1 antibody and a ribosome inactivating protein from Saponaria officinalis: potent anti-tumor effects in-vitro. J Natl Cancer Inst 75:151–159
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lahaniatis, J.E., Brady, L.W. (2003). Immunotherapy for Primary Brain Tumors. In: Petrovich, Z., Brady, L.W., Apuzzo, M.L.J., Bamberg, M. (eds) Combined Modality Therapy of Central Nervous System Tumors. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56411-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-56411-6_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00627-5
Online ISBN: 978-3-642-56411-6
eBook Packages: Springer Book Archive